SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 1-Year High – Here’s What Happened
by Teresa Graham · The Cerbat GemSELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $4.80 and last traded at $4.8740, with a volume of 5994881 shares trading hands. The stock had previously closed at $4.35.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.00.
Check Out Our Latest Report on SELLAS Life Sciences Group
SELLAS Life Sciences Group Price Performance
The business’s 50-day simple moving average is $2.03 and its two-hundred day simple moving average is $1.90. The stock has a market cap of $723.03 million, a price-to-earnings ratio of -18.13 and a beta of 2.26.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. Equities research analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.
Insider Transactions at SELLAS Life Sciences Group
In other SELLAS Life Sciences Group news, Director Katherine Bach Kalin acquired 63,400 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the acquisition, the director directly owned 104,400 shares in the company, valued at $165,996. This represents a 154.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.20% of the stock is currently owned by company insiders.
Institutional Trading of SELLAS Life Sciences Group
Institutional investors and hedge funds have recently bought and sold shares of the stock. Blair William & Co. IL acquired a new position in SELLAS Life Sciences Group during the 2nd quarter worth about $35,000. Simon Quick Advisors LLC bought a new position in shares of SELLAS Life Sciences Group during the second quarter worth about $44,000. ProShare Advisors LLC acquired a new position in shares of SELLAS Life Sciences Group in the second quarter worth approximately $43,000. Geode Capital Management LLC boosted its holdings in SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock valued at $4,819,000 after acquiring an additional 1,379,988 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in SELLAS Life Sciences Group in the second quarter valued at approximately $51,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.
SELLAS Life Sciences Group Company Profile
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.
The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.